Trial reportIndian journal of ophthalmology2026
A prospective, randomized study comparing different therapeutic modalities for acute adenoviral conjunctivitis.
Trial report in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the outcomes of three different therapeutic modalities in acute adenoviral conjunctivitis.
designProspective randomized study.
methodsA total of 65 eyes of 65 patients with nested polymerase chain reaction (PCR)-proven adenoviral conjunctivitis were enrolled. The control group (20 eyes) received carbomer gel, whereas the treatment group (15 eyes each) received group 1: Ganciclovir (0.15%) gel five times/day and dexamethasone 0.1% four times/day; group 2: Povidone-iodine (PVP-I) 1% four times/day, and dexamethasone 0.1% four times/day; group 3: PVP-I 1% four times/day, ganciclovir 0.15% five times/day, and dexamethasone 0.1% four times/day in addition to the standard of care. Patients presenting within the first 96 hours were recruited, and antiviral treatment was given for seven days in all groups. The clinical signs and symptoms, as well as the viral load, were documented at enrollment, day 7, and day 14. All the symptoms and signs were graded.
resultsGroup 3 performed significantly better in terms of foreign body sensation ( P = 0.013), pain ( P = 0.019), and conjunctival congestion ( P = 0.00) compared with all the groups at day 7. The control group had a significantly higher number of subepithelial infiltrates (SEIs) ( P = 0.0001) and pseudomembranes ( P = 0.035) at day 7 than all the other groups. The viral load reduction was variable in all patients in all the groups; thus, a correlation could not be achieved.
conclusionThe combination of PVP-I 1% and ganciclovir 0.15% with dexamethasone 0.1% significantly reduced the severity of signs and symptoms in adenoviral conjunctivitis. The addition of dexamethasone was safe and effective in decreasing the incidence of SEI's and pseudomembranes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.